Market Research Logo

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2016

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2016’, provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)
    • The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Congestive Heart Failure (Heart Failure) therapeutics and enlists all their major and minor projects
    • The report assesses Congestive Heart Failure (Heart Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Congestive Heart Failure (Heart Failure) Overview
    Therapeutics Development
    Pipeline Products for Congestive Heart Failure (Heart Failure) - Overview
    Pipeline Products for Congestive Heart Failure (Heart Failure) - Comparative Analysis
    Congestive Heart Failure (Heart Failure) - Therapeutics under Development by Companies
    Congestive Heart Failure (Heart Failure) - Therapeutics under Investigation by Universities/Institutes
    Congestive Heart Failure (Heart Failure) - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Congestive Heart Failure (Heart Failure) - Products under Development by Companies
    Congestive Heart Failure (Heart Failure) - Products under Investigation by Universities/Institutes
    Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development
    Amgen Inc.
    AnGes MG, Inc.
    Araim Pharmaceuticals, Inc.
    ARCA biopharma, Inc.
    Ascelegen Therapeutics, Inc.
    Asterias Biotherapeutics, Inc.
    Athersys, Inc.
    Bayer AG
    BEAT BioTherapeutics Corp.
    BioCardia, Inc.
    Bristol-Myers Squibb Company
    Capricor Therapeutics, Inc.
    Cell Therapy Limited
    Celyad SA
    Eli Lilly and Company
    FibroGen, Inc.
    GlaxoSmithKline Plc
    Glucox Biotech AB
    Heart Metabolics Limited
    Hemostemix Ltd
    Innopharmax Inc.
    Jiangsu Hengrui Medicine Co., Ltd.
    Juventas Therapeutics, Inc.
    La Jolla Pharmaceutical Company
    Laboratoires Pierre Fabre SA
    Lead Discovery Center GmbH
    Lee's Pharmaceutical Holdings Limited
    Les Laboratoires Servier SAS
    Lonestar Heart, Inc.
    Mast Therapeutics, Inc.
    Merck & Co., Inc.
    Mesoblast Limited
    miRagen Therapeutics, Inc.
    MorphoSys AG
    NanoCor Therapeutics, Inc.
    Neurocrine Biosciences, Inc.
    Novartis AG
    Nuo Therapeutics, Inc.
    Ono Pharmaceutical Co., Ltd.
    Palatin Technologies, Inc.
    Pfizer Inc.
    PharmaIN Corporation
    PhaseBio Pharmaceuticals, Inc.
    Pluristem Therapeutics Inc.
    Quantum Genomics SA
    Recardio GmbH
    RedHill Biopharma Ltd.
    Renova Therapeutics Inc
    scPharmaceuticals Inc
    Stealth BioTherapeutics Inc.
    Stemedica Cell Technologies, Inc.
    Target Heart Biotec Srl
    Theravance Biopharma, Inc.
    TiGenix NV
    Torrent Pharmaceuticals Limited
    Trevena, Inc.
    U.S. Stem Cell, Inc.
    Vichem Chemie Research Ltd.
    Vicore Pharma AB
    Zensun (Shanghai) Sci & Tech Co., Ltd.
    Congestive Heart Failure (Heart Failure) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (sacubitril + valsartan) - Drug Profile
    AAVS-100A1 - Drug Profile
    ACP-01 - Drug Profile
    AdipoCell - Drug Profile
    aladorian sodium - Drug Profile
    ALD-201 - Drug Profile
    AMG-986 - Drug Profile
    AntimiR-199a - Drug Profile
    ARX-720 - Drug Profile
    BAY-868050 - Drug Profile
    BBR-12 - Drug Profile
    beperminogene perplasmid - Drug Profile
    BMS-986231 - Drug Profile
    bucindolol hydrochloride - Drug Profile
    C-21 - Drug Profile
    C3BSCQR-1 - Drug Profile
    CAP-1002 - Drug Profile
    Carfostin - Drug Profile
    carvedilol CR - Drug Profile
    carvedilol phosphate CR - Drug Profile
    cenderitide - Drug Profile
    cibinetide - Drug Profile
    CLR-325 - Drug Profile
    CM-1 - Drug Profile
    CTX-101 - Drug Profile
    Drug to Inhibit Calpain for Heart Failure - Drug Profile
    Drug to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure - Drug Profile
    Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile
    ECR-A1 - Drug Profile
    elamipretide - Drug Profile
    enalapril maleate - Drug Profile
    F-373280 - Drug Profile
    FG-6874 - Drug Profile
    FG-8205 - Drug Profile
    furosemide - Drug Profile
    GDF-11 - Drug Profile
    Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure - Drug Profile
    Gene Therapy to Activate GLP-1 for Congestive Heart Failure - Drug Profile
    Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile
    Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile
    Gene Therapy to Inhibit Mef2 for Heart Failure - Drug Profile
    Gene Therapy to Target mAKAPbeta for Heart Failure - Drug Profile
    GSK-2798745 - Drug Profile
    istaroxime - Drug Profile
    ITD-1 - Drug Profile
    ivabradine hydrochloride - Drug Profile
    ivabradine hydrochloride SR - Drug Profile
    JVS-100 - Drug Profile
    KBP-5074 - Drug Profile
    L-2286 - Drug Profile
    MGN-9103 - Drug Profile
    milrinone ER - Drug Profile
    Monoclonal Antibody to Inhibit Periostin1 for Congestive Heart Failure - Drug Profile
    MP-3167 - Drug Profile
    MPC-150IM - Drug Profile
    MRS-2339 - Drug Profile
    MyoCell - Drug Profile
    MyoCell SDF-1 - Drug Profile
    NBI-69734 - Drug Profile
    neladenoson bialanate - Drug Profile
    Neucardin - Drug Profile
    NM-922 - Drug Profile
    NPA-7 - Drug Profile
    Oligonucleotides for Heart Failure - Drug Profile
    omecamtiv mecarbil MR - Drug Profile
    ONO-4232 - Drug Profile
    PB-1046 - Drug Profile
    Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile
    Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure - Drug Profile
    perhexiline maleate - Drug Profile
    PF-05285401 - Drug Profile
    PHIN-1138 - Drug Profile
    PL-3994 - Drug Profile
    PLX-PAD - Drug Profile
    poloxamer - Drug Profile
    pyroglutaminated serpinin - Drug Profile
    QGC-101 - Drug Profile
    REC-02 - Drug Profile
    Recombinant Protein for Congestive Heart Failure - Drug Profile
    rivaroxaban - Drug Profile
    RT-100 - Drug Profile
    RT-110 - Drug Profile
    RT-300 - Drug Profile
    RT-400 - Drug Profile
    ruboxistaurin - Drug Profile
    S-38844 - Drug Profile
    serelaxin - Drug Profile
    serpinin - Drug Profile
    SG-1002 - Drug Profile
    sildenafil citrate - Drug Profile
    Small Molecule for Target RhoGEF12 for Cardiovascular Disease - Drug Profile
    Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile
    Small Molecule to Inhibit NOX-4 for Heart Failure - Drug Profile
    Small Molecule to Inhibit ROMK for Hypertension and Heart Failure - Drug Profile
    Small Molecules for Chronic Heart Failure - Drug Profile
    Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile
    Small Molecules for Diastolic Heart Failure - Drug Profile
    Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile
    Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile
    Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile
    Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile
    Small Molecules to Inhibit GRK2 for Heart Failure - Drug Profile
    Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile
    Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile
    Small Molecules to Taregt Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders - Drug Profile
    sodium nitrite - Drug Profile
    SP-20202 - Drug Profile
    Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile
    Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile
    Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease - Drug Profile
    Stem Cell Therapy for Heart failure - Drug Profile
    Stem Cell Therapy for Heart Failure - Drug Profile
    Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile
    Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile
    Synthetic Peptide to Agonise Beta 2 Adrenergic Receptor for Congestive Heart Failure - Drug Profile
    Synthetic Peptide to Agonize Guanylate Cyclase A for Cardiovascular Disorders - Drug Profile
    TD-0714 - Drug Profile
    TR-4 - Drug Profile
    TRC-4186 - Drug Profile
    TRV-120023 - Drug Profile
    ularitide - Drug Profile
    VCP-746 - Drug Profile
    vepoloxamer - Drug Profile
    vericiguat - Drug Profile
    Xcel-hCardP - Drug Profile
    XEN-105 - Drug Profile
    Congestive Heart Failure (Heart Failure) - Dormant Projects
    Congestive Heart Failure (Heart Failure) - Discontinued Products
    Congestive Heart Failure (Heart Failure) - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2016
    Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Development by Companies, H2 2016 (Contd..3)
    Number of Products under Development by Companies, H2 2016 (Contd..4)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Products under Development by Companies, H2 2016 (Contd..4)
    Products under Development by Companies, H2 2016 (Contd..5)
    Products under Development by Companies, H2 2016 (Contd..6)
    Products under Investigation by Universities/Institutes, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
    Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by AnGes MG, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by ARCA biopharma, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Ascelegen Therapeutics, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Asterias Biotherapeutics, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Athersys, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Company, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Cell Therapy Limited, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Celyad SA, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Eli Lilly and Company, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline Plc, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Glucox Biotech AB, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Heart Metabolics Limited, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Ltd, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Laboratoires Pierre Fabre SA, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Lead Discovery Center GmbH, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Lonestar Heart, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Mast Therapeutics, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co., Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Limited, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by miRagen Therapeutics, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by MorphoSys AG, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by NanoCor Therapeutics, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Neurocrine Biosciences, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Nuo Therapeutics, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Pfizer Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corporation, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Pluristem Therapeutics Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Quantum Genomics SA, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by RedHill Biopharma Ltd., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Renova Therapeutics Inc, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by scPharmaceuticals Inc, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Target Heart Biotec Srl, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Torrent Pharmaceuticals Limited, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Trevena, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell, Inc., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Vichem Chemie Research Ltd., H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H2 2016
    Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Congestive Heart Failure (Heart Failure) - Dormant Projects, H2 2016
    Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..1), H2 2016
    Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..2), H2 2016
    Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..3), H2 2016
    Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..4), H2 2016
    Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..5), H2 2016
    Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..6), H2 2016
    Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..7), H2 2016
    Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..8), H2 2016
    Congestive Heart Failure (Heart Failure) - Dormant Projects (Contd..9), H2 2016
    Congestive Heart Failure (Heart Failure) - Discontinued Products, H2 2016
    Congestive Heart Failure (Heart Failure) - Discontinued Products (Contd..1), H2 2016
    List of Figures
    Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2016
    Number of Products under Development for Congestive Heart Failure (Heart Failure) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Top 10 Routes of Administration, H2 2016
    Number of Products by Stage and Top 10 Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report